ABSTRACT
Background and Aims Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of chronic liver disease that accompanies obesity and the metabolic syndrome. Excess fructose consumption can initiate or exacerbate NAFLD due in part to a consequence of impaired hepatic fructose metabolism. Pre-clinical data have emphasized that fructose-induced altered gut microbiome, increased gut permeability, and endotoxemia play an important role in NAFLD, but human studies are sparse. The present study aimed to explore the relevance of these pre-clinical studies to observations in humans.
Methods We performed a classical double-blind metabolic unit study in 10 obese subjects (BMI 30-40 mg/kg/m2) providing 75gms. of either fructose or glucose in their individual diets substituted isocalorically for complex carbohydrates in a cross-over study. Excess fructose intake was provided in the fructose arm of the study and totaled a mean of 22.7% of calories.
Results Routine blood, uric acid, liver function and lipid measurements were unaffected by the fructose intervention. The fecal microbiome (including Akkermansia muciniphilia), fecal metabolites, gut permeability, indices of endotoxemia, gut damage or inflammation and plasma metabolites were essentially unchanged by either intervention.
Conclusions Although pre-clinical rodent studies have shown that excess fructose causes pronounced changes in the gut microbiome, metabolome, and permeability as well as endotoxemia, this did not occur in obese individuals fed fructose in amounts known to enhance NAFLD. Therapeutic efforts to improve NAFLD through changes in the gut microbiome and gut homeostasis may not be beneficial.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ClinicalTrials.gov Identifier, NCT03339245.
Funding Statement
This research was supported in part by RUCCTS grant # UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) Program The Sackler Center for Biomedicine and Nutrition at the Rockefeller University 1ZIANR000018, Division of Intramural Research, NIH, Department of Health and Human Services. American Heart Association 17-SFRN33520045 K08-DK117064, NIH, at New York University Langone Health. Neither the authors nor their institutions received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All necessary IRB committee approvals have been obtained from the Rockefeller University IRB. The protocol underwent full review upon initiation of the study as well as annual reviews thereafter. All adverse events were submitted in a timely manner. RU protocol #PHO-0956
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability statement All individual participant data collected during the trial, after de-identification, including text, tables, figures, and supplemental material, will be available after publication to anyone who wishes to access the data. Data are available upon reasonable request to: Dr Peter R. Holt, holtp{at}rockefeller.edu. Dr. Jose O. Aleman, Jose.Aleman{at}nyulangone.org. ClinicalTrials.gov Identifier, NCT03339245.
Data Availability
All individual participant data collected during the trial, after de-identification, including text, tables, figures, and supplemental material, will be available after publication to anyone who wishes to access the data. Data are available upon reasonable request to: Dr Peter R. Holt, holtp{at}rockefeller.edu. ORCID identifier 0000-0002-8469-2766 or Dr. Jose O. Aleman, Jose.Aleman{at}nyulangone.org. ORCID identifier 0000-0003-3753-6717.
